ArticleBiotechnology letters2024
Coselection of BAC for Escherichia coli chromosomal DNA multiplex automated genome engineering.
Article in Biotechnology letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hierarchical metabolic engineering for rewiring cellular metabolism.FEMS microbiology reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Recombineering (recombination-mediated genetic engineering) is a powerful strategy for bacterial genomic DNA and plasmid DNA modifications. CoS-MAGE improved over MAGE (multiplex automated genome engineering) by co-electroporation of an antibiotic resistance repair oligo along with the oligos for modification of the Escherichia coli chromosome. After several cycles of recombineering, the sub-population of mutants were selected among the antibiotic resistant colonies. However, a pre-generated strain with mutS deletion and multiple inactivated antibiotic resistance genes integration is required. Herein, CoS-MAGE was modified by employing a single copy BAC vector harboring a bla-mkan cassette and a Red helper vector cloned with dominant mutL E32K, thus bypassing the utilization of the pre-generated strain. The proof-of-concept of the new strategy, CoS-BAC-MAGE, was demonstrated via the mutation of non-essential genes, essential genes, and AT rich regions of the wild type strain E. coli MG1655. With this system, an editing efficiency of 60% was realized. Furthermore, by toggling between two antibiotic resistance genes (one active, the other defective) on the BAC, sequential mutations were achieved without the requirement of BAC vector elimination and re-transformation. Via CoS-BAC-MAGE, simultaneously mutations of three sites were obtained in a day. We envision that CoS-BAC-MAGE will be a practical improvement for the generation of chromosomal mutations using the Cos-MAGE approach.
Indexed as
Identifiers
39725731What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.